Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Nabriva Therape Ads (NBRV)

1.79   0.04 (2.29%) 03-07 04:45
Open: 1.75 Pre. Close: 1.75
High: 1.84 Low: 1.52
Volume: 3,482,013 Market Cap: 62M
Nabriva Therapeutics plc, a biopharmaceutical company, engages in the development and commercialization of novel anti-infective agents to treat serious infections. The company's lead product candidate is lefamulin, a semi-synthetic pleuromutilin antibiotic for the treatment of community-acquired bacterial pneumonia; for the treatment of acute bacterial skin and skin structure infection; and that is in Phase I clinical trial for the treatment of pediatric infections, as well as sexually transmitted infections, osteomyelitis, and prosthetic joint infections. It is also developing CONTEPO, an epoxide antibiotic for use in treating complicated urinary tract infections, as well as is in Phase I clinical trial for peri-operative prophylaxis. The company was formerly known as Nabriva Therapeutics Forschungs GmbH and changed its name to Nabriva Therapeutics plc in 2007. Nabriva Therapeutics plc was incorporated in 2005 and is headquartered in Dublin, Ireland.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 1.841 - 1.85 1.85 - 1.858
Low: 1.501 - 1.51 1.51 - 1.518
Close: 1.774 - 1.789 1.789 - 1.804

Technical analysis

as of: 2021-03-05 5:11:04 PM
Overall:       
Stoxline posted a NEUTRAL today, upgraded from lower rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell.
Target: Six months: 3.20     One year: 4.08
Support: Support1: 1.52    Support2: 1.26
Resistance: Resistance1: 2.74    Resistance2: 3.49
Pivot: 2.51
Moving Average: MA(5): 1.87     MA(20): 2.67
MA(100): 3.57     MA(250): 5.43
MACD: MACD(12,26): -0.30     Signal(9): -0.18
Stochastic oscillator: %K(14,3): 7.75     %D(3): 5.89
RSI: RSI(14): 24.52
52-week: High: 14.10  Low: 1.52  Change(%): -86.6
Average Vol(K): 3-Month: 163632  10-Days: 420396

Price, moving averages and Bollinger Bands

Price and moving averages has closed below its Short term moving average. Short term moving average is currently below mid-term; AND below long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BEARISH in short-term; and BEARISH in mid-long term.
NBRV has closed above bottom band by 15.4%. Bollinger Bands are 69.7% wider than normal. The large width of the bands suggest high volatility as compared to NBRV's normal range. The bands have been in this wide range for 3 bars. This is a sign that the current trend might continue.

Headline News

Thu, 25 Feb 2021
Nabriva Therapeutics (NASDAQ:NBRV) Upgraded to "Buy" by Zacks Investment Research - MarketBeat

Mon, 01 Feb 2021
Nabriva Therapeutics Announces Retirement of its Chief Financial Officer - GlobeNewswire

Thu, 10 Dec 2020
Nabriva Therapeutics Announces Pricing of $15 Million Public Offering - GlobeNewswire

Thu, 10 Dec 2020
Nabriva Therapeutics Announces Proposed Public Offering Nasdaq:NBRV - GlobeNewswire

Mon, 07 Dec 2020
Nabriva Therapeutics and Sinovant Sciences Restructure License Agreement for XENLETA for Community-Acquired Bacterial Pneumonia in China - GlobeNewswire

Thu, 12 Nov 2020
Nabriva Therapeutics to Participate in Upcoming Virtual Investor Conferences - GlobeNewswire

Financial Analysis

Growth
Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing.
Profitability
Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs.
Solvency
Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry.
Efficiency
Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not.
Price to Book Value: Outperform Discounted cash flow: Outperform
Return on Assets: Underperform Price to Earnings: Underperform
Return on Equity: Underperform Debt to Equity: Outperform
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. (M) 21
Shares Float (M) 15
% Held by Insiders 0.45
% Held by Institutions 20.72
Shares Short (K) 442
Shares Short P. Month (K) 645

Stock Financials

EPS -6.905
EPS Est This Year -2.290
EPS Est Next Year -1.990
Book Value (p.s.) 2.410
Profit Margin
Operating Margin -2411.31
Return on Assets (ttm) -59.5
Return on Equity (ttm) -198.0
Qtrly Rev. Growth -81.3
Gross Profit (p.s.) -0.806
Sales Per Share 0.138
EBITDA (p.s.) -3.291
Qtrly Earnings Growth
Operating Cash Flow (M) -73
Levered Free Cash Flow (M) -47

Stock Valuations

PE Ratio -0.26
PEG Ratio
Price to Book value 0.74
Price to Sales 13.01
Price to Cash Flow -0.51

Stock Dividends

Dividend
Forward Dividend
Dividend Yield
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
7 Binary Options
Your Ad Here
android_stock_chart
Stock Chart
stoxline_lite
Stoxline Lite
stoxline_pro
Stoxline Pro
Option_Calculator
Option Calculator
(c) 2006-2020 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.